Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

26.92 -0.64 (-2.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,608,061
Open 27.78
Bid (Size) 26.92 (5)
Ask (Size) 27.90 (1)
Prev. Close 27.56
Today's Range 26.26 - 27.78
52wk Range 26.35 - 41.61
Shares Outstanding 57,031,297
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents an 'Affordable Growth' Opportunity
Harmony Biosciences (HRMY) offers affordable growth with strong EPS & revenue expansion, a low P/E ratio, and robust profitability in rare neurological treatments. 
Via Chartmill
Deep Dive Into Harmony Biosciences Hldgs Stock: Analyst Perspectives (6 Ratings)
Analysts' ratings for Harmony Biosciences Hldgs (NASDAQ: HRMY) over the last quarter vary from bullish to bearish, as provided by 6 analysts. Summarizing their recent assessments, the table below... 
Via Benzinga

Performance

YTD
-22.7%
-22.7%
1 Month
-27.4%
-27.4%
3 Month
-16.0%
-16.0%
6 Month
-17.0%
-17.0%
1 Year
-32.7%
-32.7%

More News

Read More
Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday
Via Benzinga
Harmony Biosciences Stock Slumps After Rare Genetic Disorder Drug Fails Late-Stage Study
Via Stocktwits
Earnings Scheduled For August 5, 2025
Via Benzinga
Harmony Biosciences' Genetic Disorder Drug Disappoints In Phase 3 Study
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Harmony Biosciences Whiffs In 'Undruggable' Genetic Disease; Shares Tumble
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Opportunity
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Top Affordable Growth Stock
Via Chartmill
Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Opportunity
Via Chartmill
Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Holdings (NASDAQ:HRMY): A Prime Affordable Growth Stock with Strong Fundamentals
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY): A Strong Growth Stock with Promising Technical Setup
Via Chartmill
Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Opportunity with Strong Fundamentals and Growth Potential
Via Chartmill
Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Growth Stock with Attractive Valuation
Via Chartmill
Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series
From Harmony Biosciences
Via Business Wire
6 Analysts Assess Harmony Biosciences Hldgs: What You Need To Know
Via Benzinga
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
Via Investor's Business Daily
Topics Intellectual Property
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) – An Undervalued Stock with Strong Fundamentals
Via Chartmill

Frequently Asked Questions

Is Harmony Biosciences Holdings, Inc. - Common Stock publicly traded?
Yes, Harmony Biosciences Holdings, Inc. - Common Stock is publicly traded.
What exchange does Harmony Biosciences Holdings, Inc. - Common Stock trade on?
Harmony Biosciences Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Harmony Biosciences Holdings, Inc. - Common Stock?
The ticker symbol for Harmony Biosciences Holdings, Inc. - Common Stock is HRMY on the Nasdaq Stock Market
What is the current price of Harmony Biosciences Holdings, Inc. - Common Stock?
The current price of Harmony Biosciences Holdings, Inc. - Common Stock is 26.92
When was Harmony Biosciences Holdings, Inc. - Common Stock last traded?
The last trade of Harmony Biosciences Holdings, Inc. - Common Stock was at 10/01/25 04:00 PM ET
What is the market capitalization of Harmony Biosciences Holdings, Inc. - Common Stock?
The market capitalization of Harmony Biosciences Holdings, Inc. - Common Stock is 1.54B
How many shares of Harmony Biosciences Holdings, Inc. - Common Stock are outstanding?
Harmony Biosciences Holdings, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.